Researchers are testing the effectiveness of Metformin to help improve daily living for individuals with Fragile X syndrome.

The trial further assesses Metformin’s safety, as well as the benefits of the drug, which has been shown to improve the symptoms and difficulties individuals with FXS experience, including: delayed language/cognition, excessive eating, obesity, hypogonadism, and delayed puberty.


Who can participate?

Individuals aged 6–25 who have been diagnosed with FXS (and who fit the inclusion/exclusion criteria).

What will happen in the study?

Commit to a four-month study which includes three clinic visits, and five phone calls while taking Metformin orally. Complete various tasks, questionnaires, and examinations by a physician/research team, as well as have blood drawn, as well as urine and stool samples taken.

Will you/your child be paid to complete this survey?

Travel expenses will be reimbursed.

Study doctors and locations

Please fill out the form below to send your contact information to the study coordinators.

Dr. Francois Bolduc, Principal Investigator
University of Alberta/Stollery Children’s Hospital
Edmonton, Alberta, Canada

Clinical Research Coordinator: Call (780) 492-9461 or email

Dr. Sébastien Jacquemont, Principal Investigator
CHU Ste. Justine
Montreal, Quebec, Canada

Study Coordinators: Maryse Thibeault or Sophie Morin

If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.
View More Opportunities

Parent Survey: Children’s Behavioral Strengths and Challenges

The MIND Group at the University of Minnesota is conducting a survey for parents of children with Fragile X syndrome to learn about how genetic and neurodevelopmental differences impact behavioral strengths and challenges. Parents of 3–17 year old children living with Fragile X are eligible to participate.

Study: Language Environment Analysis Project (LEAP)

Purdue University is conducting a research study to learn about language and social communication development in Fragile X syndrome. Children ages 3–4 years (36–60 months) with the full mutation may be eligible to participate.

Purdue Early Childhood Study – PANDABox

Purdue University is conducting a research study to learn about development of infants with Fragile X syndrome. Boys and girls ages 6-18 months with the full mutation may be eligible to participate.

Fragile X Premutation Carrier Study at University of Kansas

The University of Kansas BRAIN Lab is conducting a research study to learn about behavioral and brain differences associated with premutations of the Fragile X gene, FMR1. Individuals ages 50–80 with the FMR1 gene premutation with or without FXTAS may be eligible to participate.